Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,224.8	$ 2,913.7
Marketable securities	1,355.0	1,562.2
Accounts receivable, net	2,024.9	1,880.5
Due from anti-CD20 therapeutic programs	527.2	590.2
Inventory	1,027.7	804.2
Other current assets	683.5	631.0
Total current assets	7,843.1	8,381.8
Marketable securities	1,009.8	1,408.1
Property, plant and equipment, net	3,359.9	3,247.3
Operating lease assets	434.2	427.0
Intangible assets, net	3,323.6	3,527.4
Goodwill	5,755.7	5,757.8
Deferred tax asset	1,372.9	3,232.1
Investments and other assets	1,834.9	1,252.8
Total assets	24,934.1	27,234.3
Current liabilities:
Current portion of notes payable	0.0	1,495.8
Taxes payable	119.4	71.4
Accounts payable	398.4	530.8
Accrued expenses and other	3,286.2	2,765.8
Total current liabilities	3,804.0	4,863.8
Notes payable	7,425.0	4,459.0
Deferred tax liability	1,123.4	2,810.8
Long-term operating lease liabilities	409.1	412.7
Other long-term liabilities	1,428.1	1,348.9
Total liabilities	14,189.6	13,895.2
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	0.0
Accumulated other comprehensive loss	(225.5)	(135.2)
Retained earnings	13,961.0	16,455.4
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	10,758.5	13,343.2
Noncontrolling interests	(14.0)	(4.1)
Total equity	10,744.5	13,339.1
Total liabilities and equity	$ 24,934.1	$ 27,234.3